Transdermal Estrogen in High-Risk Patients: When Science, Safety, and Patient Autonomy Matter Most

Hormone therapy decisions are rarely simple. But for some patients, they are especially complex.

Consider the postmenopausal woman with clotting disorder(s)

At first glance, estrogen therapy may feel “off the table” to many clinicians—often due to long-standing fear around clotting risk. But modern evidence tells a more nuanced story, especially when we distinguish oral estrogen from transdermal estrogen.

This is where updated science matters.

Why Route of Estrogen Matters

Estrogen therapy is not one-size-fits-all. One of the most important distinctions is how estrogen is delivered.

Oral estrogen:

• Undergoes first-pass hepatic metabolism

• Increases production of clotting factors

• Increases resistance to activated protein C

• Consistently associated with higher venous thromboembolism (VTE) risk

Transdermal estrogen (patch, gel, spray):

• Bypasses the liver

• Has minimal effect on coagulation factors

• Does not significantly increase VTE risk in most studies—even in higher-risk populations

This distinction is not theoretical. It is supported by decades of mechanistic, observational, and clinical research.

What the Research Actually Shows

1. Transdermal Estrogen and Thrombophilia

Multiple studies demonstrate that transdermal estrogen does not significantly increase VTE risk, even in women with inherited clotting disorders.

A landmark case-control study evaluating women with Factor V Leiden found:

• Oral estrogen + mutation → dramatic increase in VTE risk

• Transdermal estrogen + mutation → no significant increase in VTE risk compared to non-users

This strongly suggests that route of administration—not estrogen itself—is the primary driver of clot risk.

2. Systematic Reviews in High-Risk Women

Systematic and scoping reviews evaluating menopausal hormone therapy in women at elevated thrombotic risk consistently conclude:

• Oral estrogen increases VTE risk

• Transdermal estrogen appears neutral with respect to clot risk

• Transdermal estrogen is the preferred option when estrogen is indicated in higher-risk patients

While randomized controlled trials in this specific population are limited (for ethical and practical reasons), the totality of evidence supports transdermal estrogen as the safer option.

3. Protein S Deficiency: What We Know and Don’t Know

Data specific to protein S deficiency are more limited than for Factor V Leiden. However:

• Protein S deficiency increases baseline clot risk

• Oral estrogen further worsens coagulation balance

• Transdermal estrogen does not appear to significantly disrupt anticoagulant pathways

In practice, recommendations for protein S deficiency are extrapolated from broader thrombophilia data—and still favor transdermal estrogen when estrogen is used.

The Bigger Picture: This Is About Autonomy, Not Dogma

At the end of the day, hormone therapy is not about rigid rules.It is about:

• Up-to-date science

• Individualized risk assessment

• Informed patient choice

Bias—whether rooted in outdated studies, fear of litigation, or decades-old training—has no place in modern menopause care.

Patients deserve:

• Honest discussions of relative vs absolute risk

• Clear differentiation between oral and transdermal estrogen

• The opportunity to weigh benefits and risks in the context of their own values and quality of life

Clinicians are not here to gatekeep therapy. We are here to guide, educate, and partner.

Final Thoughts

Transdermal estrogen is not risk-free—but neither is untreated osteoporosis, recurrent fractures, or unmanaged menopausal symptoms.

For high-risk patients, the question should not be:

“Is estrogen allowed?”

It should be:

“What is the safest, most evidence-based way to treat this patient?”

When decisions are grounded in science—not fear—patients regain agency. And that is the heart of ethical, modern hormone care.

With Love,

The MenoPower Chick